Xperix Acquires Bagel Labs, the World’s First Commercializer of Digital Convergence Pharmaceuticals

On September 15, Xperix, an artificial intelligence (AI)-based solutions company, announced that it has acquired Bagel Labs, a digital therapeutics (DTx) specialist that built the world’s first commercialization model for digital convergence pharmaceuticals, marking its entry into the global AI healthcare market.

Through this acquisition, Xperix plans to accelerate its ongoing joint research and development of obesity digital convergence pharmaceuticals with Hanmi Pharmaceutical, aiming to establish itself as an AI healthcare company that not only meets but exceeds market expectations by delivering tangible results.

By acquiring Bagel Labs, Xperix has secured management control and the position of largest shareholder, and will leverage its successful experience in AI to expand into the new business area of healthcare. This move goes beyond simple business diversification, representing a strategic step to create synergy by combining Xperix’s AI capabilities with Bagel Labs’ medical expertise.

To this end, Park Suhong, CEO of Bagel Labs, has joined Xperix as an internal director and Chief AI Officer (CAIO), while Professor Moon Youngwan of the Department of Orthopedic Surgery at Samsung Medical Center has joined as an outside director. Through these appointments, Xperix plans to strengthen both its technological capabilities and clinical reliability, internalizing the entire process from clinical validation to commercialization.

Newly appointed CAIO Park Suhong is an expert in AI and automation systems, having studied Biomechanics and Applied Mathematics at Johns Hopkins University in the United States and earned a doctorate in Engineering from the University of Cambridge in the United Kingdom. He will lead Xperix’s AI healthcare business, drawing on his experience developing image recognition-based process automation systems at Corning Precision Materials and his expertise in commercializing digital therapeutics through the founding of Bagel Labs.

Outside director Moon Youngwan is currently the Director of the Joint Center and Head of the Department at Samsung Medical Center, and is recognized as the nation’s leading authority in the field of knee joints. He is expected to further deepen Xperix’s medical expertise by leveraging his extensive experience in actively introducing advanced medical technologies such as robotic joint replacement surgery into clinical practice.

Yoon Sangchul, CEO of Xperix, stated, “This acquisition is an important first step in expanding our AI technology into the healthcare sector. Starting with the research and development of obesity digital convergence pharmaceuticals, which is already delivering visible results in collaboration with Hanmi Pharmaceutical, we will combine our proven platform with world-class experts to usher in a new paradigm of personalized healthcare.”